Your session is about to expire
← Back to Search
This trial is testing a new medication to find a safe dose to use in further studies. Up to 12 people will be involved in each group.
- Ovarian Cancer
- Ovarian Tumors
- Peritoneal Tumors
- Fallopian Tube Cancer
- Genital Warts
- Abdominal Tumors
- Ovarian Disease
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have fluid buildup in your chest or abdomen that cannot be treated with usual methods.You have a brain tumor that hasn't been treated yet.
- Group 1: AB-1015
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still slots available for those wishing to participate in this experiment?
"Affirmative. Clinicaltrials.gov displays that this research endeavour, initially posted on November 1st 2022, is currently recruiting volunteers. Approximately 60 subjects need to be signed up from a single site."
Has AB-1015 been sanctioned by the FDA?
"Our team at Power gave AB-1015 a score of 1 since it is only in its first phase, thus there is limited evidence for safety and efficacy."
What is the current intake of participants for this research endeavor?
"Affirmative, the clinical trial is actively recruiting as per data available on clinicaltrials.gov. This research project was originally published on November 1st 2022 and modified most recently on November 18th 2022. Presently, 60 participants are needed to be recruited from a single medical centre."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- UCSF Helen Diller Family Comprehensive Cancer Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends